Zobrazeno 1 - 10
of 50
pro vyhledávání: '"Paul Severson"'
Autor:
Lauren Lee, Yoshiyuki Hizukuri, Paul Severson, Benjamin Powell, Chao Zhang, Yan Ma, Maiko Narahara, Hiroyuki Sumi, Daniela Hernandez, Trivikram Rajkhowa, Gideon Bollag, Mark Levis
Publikováno v:
Haematologica, Vol 106, Iss 4 (2021)
Acute myeloid leukemia patients with FLT3-ITD mutations have a high risk of relapse and death. FLT3 tyrosine kinase inhibitors improve overall survival, but their efficacy is limited and most patients who relapse will ultimately die of the disease. E
Externí odkaz:
https://doaj.org/article/c7f8f09f91644b7dbf60b170ee0a7323
Autor:
Robert Wesolowski, Neelesh Sharma, Laura Reebel, Mary Beth Rodal, Alexandra Peck, Brian L. West, Adhirai Marimuthu, Paul Severson, David A. Karlin, Afshin Dowlati, Mai H. Le, Lisa M. Coussens, Hope S. Rugo
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 11 (2019)
Purpose: To evaluate the safety, recommended phase II dose (RP2D) and efficacy of pexidartinib, a colony stimulating factor receptor 1 (CSF-1R) inhibitor, in combination with weekly paclitaxel in patients with advanced solid tumors. Patients and Meth
Externí odkaz:
https://doaj.org/article/26e5bc3db4084f12bdaf56d54e8bff23
Autor:
Rosa Lapalombella, John C. Byrd, Gideon Bollag, Ewy A. Mathé, Chao Zhang, Prabha Ibrahim, Gaston Habets, Bernice Matusow, Marika Nespi, Hamid Rezaei, Laura Sanftner, Jason Walters, Christina Tantoy, Adhirai Marimuthu, Todd Ewing, Ken Dong, Garson Tsang, Heidi Carias, Rafe Shellooe, Paul Severson, Songyuan Shi, Wayne Spevak, Ying Zhang, Yan Ma, Jiazhong Zhang, Lianbo Yu, Amy M. Lehman, Deepa Sampath, Jennifer A. Woyach, David M. Lucas, Virginia M. Goettl, Larry Beaver, Matthew Cannon, Elizabeth Baskin, Lindsey Brinton, Robert A. Baiocchi, Lapo Alinari, Tzung-Huei Lai, Katie Williams, Nicole R. Grieselhuber, Shaneice Mitchell, Bonnie Harrington, James S. Blachly, Zachary A. Hing, Ben Powell, Dalia El-Gamal, Hatice Gulcin Ozer
Supplementary Figures S1-S7 with captions and Supplementary Tables
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4f7533dd2eb9678807fc10bb97d5617e
https://doi.org/10.1158/2159-8290.22532987
https://doi.org/10.1158/2159-8290.22532987
Autor:
Rosa Lapalombella, John C. Byrd, Gideon Bollag, Ewy A. Mathé, Chao Zhang, Prabha Ibrahim, Gaston Habets, Bernice Matusow, Marika Nespi, Hamid Rezaei, Laura Sanftner, Jason Walters, Christina Tantoy, Adhirai Marimuthu, Todd Ewing, Ken Dong, Garson Tsang, Heidi Carias, Rafe Shellooe, Paul Severson, Songyuan Shi, Wayne Spevak, Ying Zhang, Yan Ma, Jiazhong Zhang, Lianbo Yu, Amy M. Lehman, Deepa Sampath, Jennifer A. Woyach, David M. Lucas, Virginia M. Goettl, Larry Beaver, Matthew Cannon, Elizabeth Baskin, Lindsey Brinton, Robert A. Baiocchi, Lapo Alinari, Tzung-Huei Lai, Katie Williams, Nicole R. Grieselhuber, Shaneice Mitchell, Bonnie Harrington, James S. Blachly, Zachary A. Hing, Ben Powell, Dalia El-Gamal, Hatice Gulcin Ozer
Supplementary Methods
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0b606648bc10ea30723eacd8e307e1ba
https://doi.org/10.1158/2159-8290.22532984.v1
https://doi.org/10.1158/2159-8290.22532984.v1
Autor:
Sandra Tong-Starksen, Paul S. Lin, Brian L. West, Paul Severson, Xin Ye, Heather L. Gelhorn, Charles Peterfy, Henry H. Hsu, Eric Sherman, Fadi Braiteh, Andrew J. Wagner, Gregory M. Cote, Igor Puzanov, Zev A. Wainberg, Vicki L. Keedy, Geoffrey I. Shapiro, Allen Lee Cohn, Bartosz Chmielowski, John H. Healey, Chao Zhang, Mike Sterba, Stephen Patrick Anthony, Arun S. Singh, William D. Tap
Purpose:To assess the response to pexidartinib treatment in six cohorts of adult patients with advanced, incurable solid tumors associated with colony-stimulating factor 1 receptor (CSF1R) and/or KIT proto-oncogene receptor tyrosine kinase activity.P
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::26c23a45df4ab5ad4ce47e4769969c45
https://doi.org/10.1158/1078-0432.c.6530892
https://doi.org/10.1158/1078-0432.c.6530892
Autor:
Sandra Tong-Starksen, Paul S. Lin, Brian L. West, Paul Severson, Xin Ye, Heather L. Gelhorn, Charles Peterfy, Henry H. Hsu, Eric Sherman, Fadi Braiteh, Andrew J. Wagner, Gregory M. Cote, Igor Puzanov, Zev A. Wainberg, Vicki L. Keedy, Geoffrey I. Shapiro, Allen Lee Cohn, Bartosz Chmielowski, John H. Healey, Chao Zhang, Mike Sterba, Stephen Patrick Anthony, Arun S. Singh, William D. Tap
Supplementary Data from Results from Phase I Extension Study Assessing Pexidartinib Treatment in Six Cohorts with Solid Tumors including TGCT, and Abnormal CSF1 Transcripts in TGCT
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0e149a7afcdc68bbe63a27f167cc400b
https://doi.org/10.1158/1078-0432.22482318.v1
https://doi.org/10.1158/1078-0432.22482318.v1
Autor:
Steven DeMeester, Kenneth Wang, Kamran Ayub, F. Paul Buckley, Philip Leggett, Paul Severson, Anastasia Chahine, Jason B. Samarasena
Publikováno v:
Techniques and Innovations in Gastrointestinal Endoscopy. 24:340-350
Autor:
Alexander Spira, Valentina Gambardella, Shumei Kato, Cesar Batista Perez, Meredith Mckean, Maria Gonzalez Cao, Richard Kim, Chris T Chen, Antoine Italiano, Philippe Cassier, Janice Mehnert, Bartosz Chmielowski, Gerri Lee, Paul Severson, Caro Unger, Xiaowei Guan, Richard Williams, Georgina Long
Publikováno v:
Cancer Research. 83:CT032-CT032
Background: Patients with cancers driven by BRAF Class II (C II) or C III alterations and/or NRAS mutations are unlikely to benefit from approved BRAF-targeted therapies and have few other treatment options. Exarafenib is a potentially best in class
Autor:
Tim S. Wang, Catherine Lee, Paul Severson, Robert J. Pelham, Richard Williams, Nichol L. G. Miller
Publikováno v:
Cancer Research. 83:4927-4927
Background: MAPK activating mutations are common in melanoma, with 40% of cases attributed to oncogenic BRAF mutations and 20-25% NRAS mutations. Secondary MAPK activation is a known resistance mechanism to approved BRAF inhibitors in BRAFV600 melano
Autor:
Benjamin Garmezy, Cesar Augusto Perez, Shumei Kato, Manish Sharma, Cheng Seok Quah, Betty Tam, Paul Severson
Publikováno v:
Journal of Clinical Oncology. 41:TPS593-TPS593
TPS593 Background: FGFR1-4 gene alterations are infrequent across solid tumors though preclinical and clinical evidence indicate activating alterations drive oncogenesis and tumor growth. They can be found in up to 20% of patients with UC and up to 3